Records
Every government record, registry entry, journal paper and filing we have checked, in one list. Filter by peptide or type. Each row says what the record says, what we could not confirm, and the day we opened it.
87 records. Filters need JavaScript.
- Public comment docket HHS-OASH-2026-0496
Status: Comments open until Nov 14, 2026. Docket for the HHS draft enforcement policy on compounded peptides.
Caveat: Not re-opened in the latest check (automated access blocked). The dossier links it without a summary.
Verified Oct 31, 2026
- Public comment docket HHS-OASH-2026-0496
Status: Comments open until Nov 14, 2026. Docket for the HHS draft enforcement policy on compounded peptides.
Caveat: Not re-opened in the latest check (automated access blocked).
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. State-licensed pharmacies, federal facilities and licensed physicians would not face enforcement for compounding the listed peptides, under conditions including a patient-specific prescription and quality testing. Not FDA approval.
Caveat: The notice does not itself name the peptides; coverage of this peptide rests on a law-firm summary.
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. State-licensed pharmacies, federal facilities and licensed physicians would not face enforcement for compounding the listed peptides, under conditions including a patient-specific prescription and quality testing. Not FDA approval.
Caveat: The notice does not itself name the peptides; coverage of this peptide rests on a law-firm summary.
Verified Oct 31, 2026
- Public comment docket HHS-OASH-2026-0496
Status: Comments open until Nov 14, 2026. Docket for the HHS draft enforcement policy on compounded peptides.
Caveat: Not re-opened in the latest check (automated access blocked).
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. State-licensed pharmacies, federal facilities and licensed physicians would not face enforcement for compounding the listed peptides, under conditions including a patient-specific prescription and quality testing. Not FDA approval.
Caveat: The notice does not itself name the peptides; coverage of this peptide rests on a law-firm summary.
Verified Oct 31, 2026
- Public comment docket HHS-OASH-2026-0496
Status: Comments open until Nov 14, 2026. Docket for the HHS draft enforcement policy on compounded peptides.
Caveat: Not re-opened in the latest check (automated access blocked).
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. State-licensed pharmacies, federal facilities and licensed physicians would not face enforcement for compounding the listed peptides, under conditions including a patient-specific prescription and quality testing. Not FDA approval.
Caveat: The notice does not itself name the peptides; coverage of this peptide rests on a law-firm summary.
Verified Oct 31, 2026
- Public comment docket HHS-OASH-2026-0496
Status: Comments open until Nov 14, 2026. Docket for the HHS draft enforcement policy on compounded peptides.
Caveat: Not re-opened in the latest check (automated access blocked).
Verified Oct 31, 2026
- Public comment docket HHS-OASH-2026-0496
Status: Comments open until Nov 14, 2026. Docket for the HHS draft enforcement policy on compounded peptides.
Caveat: Not re-opened in the latest check (automated access blocked). The dossier links it without a summary.
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. State-licensed pharmacies, federal facilities and licensed physicians would not face enforcement for compounding the listed peptides, under conditions including a patient-specific prescription and quality testing. Not FDA approval. HHS says it may revisit the policy if a safety or quality problem arises.
Caveat: Draft and nonbinding. Six peptides covered; this record applies to each of them.
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. State-licensed pharmacies, federal facilities and licensed physicians would not face enforcement for compounding the listed peptides, under conditions including a patient-specific prescription and quality testing. Not FDA approval. HHS says it may revisit the policy if a safety or quality problem arises.
Caveat: Draft and nonbinding. Six peptides covered; this record applies to each of them.
Verified Oct 31, 2026
- Investigational Peptides in Orthopaedic Practice: BPC-157, Thymosin Beta-4 and TB-500
Status: Online ahead of print. Narrative review (Tham, Hodgkins and Kennedy, J Am Acad Orthop Surg) searching through June 2026. Finds human musculoskeletal evidence limited to one small retrospective uncontrolled case series and no validated dosing, pharmacokinetic or long-term safety data. Concludes routine clinical use cannot currently be recommended.
Verified Oct 31, 2026
- Investigational Peptides in Orthopaedic Practice: BPC-157, Thymosin Beta-4 and TB-500
Status: Online ahead of print. Narrative review of BPC-157, thymosin beta-4 and TB-500, searched through June 2026. Calls TB-500 a distinct seven-amino-acid fragment often conflated with full-length thymosin beta-4. Finds no FDA-approved musculoskeletal indication, product quality concerns, and concludes routine clinical use cannot currently be recommended.
Caveat: Abstract read; full text not read.
Verified Oct 31, 2026
- Early Phase 1 topical anti-aging peptide serum study, one of five peptides (Frontiers in Bioscience Research Institute and Aging)
Status: Enrolling by invitation. Planned 48 participants, one site in Irvine, California. Estimated start Oct 21, 2026. No results posted.
Caveat: Epitalon is one of five peptides in a topical serum; not an injection study.
Verified Oct 31, 2026
- Epitalon and Epithalamin: A Narrative Review (Int J Mol Sci)
Status: Published. Human evidence limited to small studies; no adequately powered randomized trial.
Caveat: Review.
Verified Oct 31, 2026
- Narrative review of BPC-157 for liver protection (Sever et al., Pharmaceuticals)
Status: Published. Summarizes animal-model findings, including on portal hypertension. The authors state that experimental evidence, however extensive, does not establish clinical efficacy.
Caveat: Author list includes Predrag Sikiric and Sven Seiwerth, who also wrote several other recent BPC-157 papers in PubMed.
Verified Oct 31, 2026
- BPC-157 pilot after rotator cuff repair (University of Arkansas)
Status: Not yet recruiting. Summary says 20 patients, enrollment field says 30.
Verified Oct 31, 2026
- A beverage with anti-fatigue and mood-regulating functions and its preparation method
Status: Published application, not granted. Applicant 南京医科大学. Filed Jul 15, 2026.
Caveat: Title as listed by Google Patents (machine translation). Legal status and claims not checked.
Verified Oct 31, 2026
- Polypeptide, polypeptide variant, preparation method, composition and application thereof
Status: Published application, not granted. Applicant 诺为泰(昆明)生物科技有限公司. Filed May 25, 2026.
Caveat: Title as listed by Google Patents (machine translation). Legal status and claims not checked; the link to BPC-157 is from the Google Patents text match.
Verified Oct 31, 2026
- Fifty 1 Labs Reg A offering (part II and III)
Status: Filed. Describes itself as a biotechnology company focused on peptide products, naming BPC-157 and TB-500.
Caveat: A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- Fifty 1 Labs Reg A offering (part II and III)
Status: Filed. Biotechnology company focused on peptide products, naming BPC-157 and TB-500.
Verified Oct 31, 2026
- Open-label BPC-157 supplement gummy study (Parlay Wellness)
Status: Completed. 40 participants, 8 weeks, no control group, registered after it ended.
Verified Oct 31, 2026
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats
Status: Published. 32 rats after Achilles tendon repair, 4 weeks. TB-500 group had higher load to failure and better tendon scores than controls; the BPC-157 and TB-500 combination added no benefit over either alone. Authors call it exploratory.
Caveat: Abstract read; full text, funding and disclosures not read.
Verified Oct 31, 2026
- Public Citizen testimony to the Pharmacy Compounding Advisory Committee about BPC-157
Status: Testimony. Argues the benefit evidence is mostly anecdotal, no trials support the proposed routes, the mechanism is unclear, and impurities could raise immune risks.
Caveat: Advocacy group testimony, not a finding. Automated access was blocked in the latest check; the summary comes from the dossier earlier read.
Verified Oct 31, 2026
- Sublingual semaglutide-BPC 157 combination for weight loss
Status: Published application, not granted. Applicant Red Mountain Med Spa, LLC. Priority May 15, 2023, filed Feb 20, 2026.
Caveat: Legal status not checked. Claims not read.
Verified Oct 31, 2026
- Spinnaker ETF Series 485APOS
Status: Filed. Risk language noting the July 23-24 FDA committee meeting would evaluate BPC-157 among other peptides.
Caveat: A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- Application of gastric pentadecapeptide in the preparation of drugs for treating immune checkpoint inhibitor-associated colitis
Status: Published application, not granted. Applicant 陕西医药控股医药研究院有限公司. Filed Apr 30, 2026.
Caveat: Title as listed by Google Patents (machine translation). Legal status and claims not checked.
Verified Oct 31, 2026
- Apparatus and method for peptide stack determination
Status: Published. Applicant: Ageless Medicine Systems. Priority Dec 10, 2024.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- BPC-157 sodium salt oral dissolving film formulation for treating acute alcohol poisoning and its preparation method
Status: Published application, not granted. Applicant 杭州昊肽生物科技有限公司. Filed Feb 6, 2026.
Caveat: Title as listed by Google Patents (machine translation). Legal status and claims not checked.
Verified Oct 31, 2026
- FDA briefing document for July 2026 advisory committee: TB-500 (free base and acetate)
Status: Proposed not to add to 503A list. No human data found. No repeat-dose, genotoxicity or carcinogenicity studies. Poorly characterized. Immunogenicity risk.
Verified Oct 31, 2026
- FDA briefing document for July 2026 advisory committee: KPV (free base and acetate)
Status: Proposed not to add to 503A list. No human data. 8 nonclinical articles submitted. Not well characterized. No FAERS reports.
Verified Oct 31, 2026
- FDA briefing document for July 2026 advisory committee: Epitalon (free base and acetate)
Status: Proposed not to add to 503A list. No clinical safety data in humans. Effectiveness for insomnia not shown. Telomerase and cancer-risk concern. No FAERS reports.
Verified Oct 31, 2026
- FDA staff briefing for the committee on BPC-157
Status: Criteria weighed against listing. Only UC use evaluated; sparse human data; animal clotting and liver signals.
Verified Oct 31, 2026
- FDA briefing document for July 2026 advisory committee: Semax (free base and acetate)
Status: Proposed not to add to 503A list. No human pharmacokinetic data. Effectiveness evidence insufficient. One FAERS consumer report (eye pain after nasal drops).
Verified Oct 31, 2026
- FDA briefing document for July 2026 advisory committee: MOTS-c (free base and acetate)
Status: Proposed not to add to 503A list. No clinical or human exposure data. Cell and rodent models only. Not well characterized. No FAERS reports.
Verified Oct 31, 2026
- BioScience Health Innovations 10-Q
Status: Filed. Filed May 11, 2026, listed alongside the 10-K on the dossier. Its contents were not summarized separately.
Caveat: Contents not separately read. A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (BPC-157)
Status: Listed. Says compounded drugs containing BPC-157 may pose immunogenicity risk for certain routes and have peptide-impurity and ingredient-characterization problems. FDA found no or only limited safety information for the proposed routes. Content current Apr 22, 2026.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (Epitalon)
Status: Listed (nominated but withdrawn). Listed under substances nominated but withdrawn. FDA has not identified safety-related information for the proposed route. Content current Apr 22, 2026.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (Semax)
Status: Listed. Immunogenicity risk for certain routes; no, or limited, safety information for proposed routes. Content current Apr 22, 2026.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (MOTS-c)
Status: Listed. Immunogenicity risk for certain routes; peptide-related impurity and characterization concerns. No human exposure data identified. Content current Apr 22, 2026.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (KPV)
Status: Listed. No human exposure data identified by FDA for any route. Content current Apr 22, 2026.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (thymosin beta-4 fragment LKKTETQ, TB-500)
Status: Listed. Immunogenicity risk for certain routes; no human exposure data identified. Content current Apr 22, 2026.
Verified Oct 31, 2026
- Simultaneous analysis of food-borne doping substances using liquid ... (a testing method; title shortened)
Status: Published application. Applicant: Korea Institute of Science and Technology. Priority Oct 7, 2024.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Phase 2a placebo-controlled MOTS-c study in prediabetes with overweight/obesity (Hudson Biotech)
Status: Recruiting. Planned 120 participants, 12 weeks subcutaneous MOTS-c vs placebo, one site in Shenzhen. Estimated primary completion Feb 2027. No results posted.
Caveat: Same sponsor as a TB-500 record whose summary calls itself fictional; this record does not contain that wording. Unverified.
Verified Oct 31, 2026
- BioScience Health Innovations 10-K
Status: Filed. Says its oral delivery system could unlock commercial pathways for formulations containing BPC-157 if FDA formally enacts a reclassification of peptides that the company describes as announced Feb 27, 2026. Lists BPC-157 among peptides it aims to deliver orally.
Caveat: A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- Phase 1/2 placebo-controlled TB-500 study in stable ASCVD (Hudson Biotech)
Status: Recruiting. Planned 80 participants, three dose cohorts, one site in Shenzhen. Estimated primary completion Feb 2027. No results posted.
Caveat: Record summary says: This fictional study is an example of a ClinicalTrials.gov-style record. Unverified.
Verified Oct 31, 2026
- A Paradise Acquisition Corp. Rule 425 (merger partner Enhanced Ltd.)
Status: Filed. A shareholder email from its merger partner, Enhanced Ltd., lists BPC-157 among peptides it intends to provide if the regulatory change occurs.
Caveat: A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- Phase 2 placebo-controlled BPC-157 in acute hamstring strain (Hudson Biotech)
Status: Recruiting. Planned 120 participants, Shenzhen, started Feb 2, 2026.
Verified Oct 31, 2026
- Synergistic combination of NAD+ and therapeutic peptides delivered via ... (title shortened by Google Patents)
Status: Published application. Applicant: Nicholas Jerome Andrews. Priority Apr 22, 2024. Second US application in the same family of titles.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Systemic MOTS-c levels are increased in adults with obesity (J Clin Transl Endocrinol)
Status: Published. 32 obese vs 22 lean adults; 10 followed after bariatric surgery. Measured levels only.
Verified Oct 31, 2026
- WADA 2026 Prohibited List, S4.4.1: mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)
Status: Prohibited
Caveat: 2022 and 2026 editions checked; 2022 does not name it.
Verified Oct 31, 2026
- WADA 2022 and 2026 Prohibited Lists: KPV not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. Section S0 covers substances with no government approval.
Verified Oct 31, 2026
- WADA 2022 and 2026 Prohibited Lists: Epitalon not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. Section S0 covers substances with no government approval.
Verified Oct 31, 2026
- WADA 2022 and 2026 Prohibited Lists: Semax not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. Section S0 covers substances with no government approval.
Verified Oct 31, 2026
- Carnyx Therapeutics Form C offering statement naming epitalon
Status: Filed. Company says its sleep program is a peptide analog of epitalon, and that epitalon is off-patent.
Caveat: Company claim, not a finding. Filing day not shown in the document; December 2025.
Verified Oct 31, 2026
- Synergistic combination of NAD+ and therapeutic peptides delivered via ... (title shortened by Google Patents)
Status: Published application. Applicant: Nicholas Jerome Andrews. Priority Apr 22, 2024. Matched TB-500 with thymosin.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Regenerative Medical Technology Group 10-Q (BPC-157 and TB-500 pen)
Status: Filed. Describes a preloaded BPC-157 and TB-500 injectable pen as its current best seller.
Caveat: A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- Regenerative Medical Technology Group 10-Q (BPC-157 and TB-500 pen)
Status: Filed. Describes a preloaded BPC-157 and TB-500 injectable pen as its current best seller.
Caveat: A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- Regenerative Medical Technology Group 10-Q (BPC-157 and TB-500 pen)
Status: Filed. Describes a BPC-157 and TB-500 injectable pen as current best seller.
Verified Oct 31, 2026
- Systematic review of BPC-157 in orthopaedic sports medicine (Vasireddi et al., HSS Journal)
Status: Published. Of 36 articles, 35 were preclinical and 1 was clinical. Authors conclude it shows promise in animal models, that human safety is unknown, and urge caution. Animal safety data covered six weeks or less.
Verified Oct 31, 2026
- Composition for tissue regeneration and wound healing containing thymosin beta- ... (title shortened by Google Patents)
Status: Published application. Applicant: Korea Institute of Science and Technology. Priority Dec 19, 2023.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Application of TB500 in the preparation of drugs for preventing or treating ... (title shortened by Google Patents)
Status: Published application. Applicant: Guangdong Ocean University. Priority Aug 30, 2023.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Quantification of TB-500 and its metabolites in vitro and in rats (UHPLC-Orbitrap MS/MS)
Status: Published. Analytical method paper with in-vitro wound-healing screening.
Caveat: Abstract read. Full text, funding and disclosures not read. Dated from PubMed (issue date Mar 1, 2024, online Feb 7, 2024).
Verified Oct 31, 2026
- Warning letter to Warrior Labz (online seller)
Status: Issued. Its website took orders for BPC-157 (injectable and nasal spray) and TB-500, alongside SARMs and other products. Issued by FDA drug center.
Caveat: Found by web search and opened; list of letters may be incomplete. A letter states FDA position at the time, not a court finding.
Verified Oct 31, 2026
- Warning letter to Warrior Labz naming TB-500 and BPC-157
Status: Issued. Online seller offering TB-500 and BPC-157 alongside SARMs.
Caveat: Found by web search; list may be incomplete.
Verified Oct 31, 2026
- WADA 2022 Prohibited List, S0: names BPC-157 as an example of non-approved substances
Status: Prohibited. The 2022 list says the non-approved substances class covers many substances including but not limited to BPC-157. S0 already covered any substance without government approval for human therapeutic use, so the 2022 text names it as an example.
Caveat: Only the 2021 and 2022 editions were checked.
Verified Oct 31, 2026
- WADA 2022 Prohibited List, S2: Thymosin-beta4 and its derivatives e.g. TB-500
Status: Prohibited
Caveat: Only the 2022 edition was checked.
Verified Oct 31, 2026
- Warning letter to Advanced Nutriceuticals (Guyer Institute), compounder
Status: Issued. Lists BPC-157 among substances that were not nominated for the 503A bulks list.
Caveat: Found by web search and opened; list of letters may be incomplete. A letter states FDA position at the time, not a court finding.
Verified Oct 31, 2026
- Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans (J Appl Physiol)
Status: Published. Randomized exercise study, 30 volunteers; measured levels, not an injection.
Verified Oct 31, 2026
- Warning letter to Predator Nutrition (supplement seller)
Status: Issued. A product labeled to contain BPC-157 was among those FDA said were marketed with claims to mitigate, prevent or treat disease. Issued by FDA food center.
Caveat: Found by web search and opened; list of letters may be incomplete. A letter states FDA position at the time, not a court finding.
Verified Oct 31, 2026
- Warning letter to Tailor Made Compounding LLC naming Epitalon among 22 substances
Status: Issued. Compounding pharmacy inspection. FDA says drugs made from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: Found by web search and read directly. List of letters may be incomplete. A warning letter is about the firm, not a finding about the substance.
Verified Oct 31, 2026
- Warning letter to Tailor Made Compounding (compounding pharmacy)
Status: Issued. Investigators noted the pharmacy compounded products using BPC 157, among many other peptides.
Caveat: Found by web search and opened; list of letters may be incomplete. A letter states FDA position at the time, not a court finding.
Verified Oct 31, 2026
- Warning letter to Tailor Made Compounding LLC naming Semax among 22 substances
Status: Issued. Compounding pharmacy inspection. FDA says drugs made from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: Found by web search and read directly. List of letters may be incomplete. A warning letter is about the firm, not a finding about the substance.
Verified Oct 31, 2026
- The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations (Drug Test Anal)
Status: Published. Semax found in seized preparations; authors say it has not completed clinical trials.
Verified Oct 31, 2026
- Warning letter to PD Labs (compounding pharmacy)
Status: Issued. Cites compounding with BPC-157 acetate, notes it was not nominated for the 503A bulks list, and records the firm saying it would continue to compound it.
Caveat: Found by web search and opened; list of letters may be incomplete. A letter states FDA position at the time, not a court finding.
Verified Oct 31, 2026
- The efficacy of semax in the treatment of patients at different stages of ischemic stroke (Zh Nevrol Psikhiatr)
Status: Published. 110 patients; BDNF and recovery measures.
Caveat: Russian journal; English abstract only.
Verified Oct 31, 2026
- Phase 1 oral BPC-157 tablets in healthy volunteers (PharmaCotherapia)
Status: Status unknown. Planned 42 volunteers in Tijuana; last verified Oct 2015; no results.
Caveat: Month of posting approximate.
Verified Oct 31, 2026
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease (Inflamm Bowel Dis)
Status: Published. Mouse colitis models.
Caveat: Animal study.
Verified Oct 31, 2026
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (Gastroenterology)
Status: Published. Lab and cell transporter study.
Caveat: Not a human study.
Verified Oct 31, 2026
- Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa (Neuro Endocrinol Lett)
Status: Published. Abstract reports a 90% positive effect; no group sizes given.
Caveat: Small study from one research group; abstract only.
Verified Oct 31, 2026
- BPC peptide salts with organo-protective activity, the process for their preparation and their use in therapy
Status: Granted US patent (current legal status not checked). Original BPC filing family. Priority May 23, 1997, filed May 20, 1998. Inventor Predrag Sikiric, who also authors many of the BPC-157 papers in PubMed. The family was filed in more than 20 jurisdictions.
Caveat: A 1998 filing would normally expire about 20 years after filing; each family member was not checked. A patent shows what an owner claims, not that a product works or is safe.
Verified Oct 31, 2026
- Effectiveness of semax in acute period of hemispheric ischemic stroke (Zh Nevrol Psikhiatr)
Status: Published. 30 Semax patients vs 80 controls.
Caveat: Russian journal; English abstract only.
Verified Oct 31, 2026
- Interstitial cystitis pilot study (Lee, Walker and Ayadi, Altern Ther Health Med)
Status: Published Oct 2024. 12 women whose previous drug had failed got a single 10 mg injection around the bladder lesion during a cystoscopy. All reported symptom relief on a questionnaire; no adverse events were reported.
Caveat: No control group. Compounding pharmacy product used. Same first author and journal as the 2025 IV report. Full text not read.
Verified Oct 31, 2026
- WADA 2021 Prohibited List (does not name BPC-157)
Status: Not named. The 2021 list does not name BPC-157.
Caveat: Included for comparison with 2022.
Verified Oct 31, 2026
- Holland & Knight: FDA advisory committee endorses compounding of certain peptides
Status: Law firm summary. Reports the July 23-24 committee recommended BPC-157 for the compounding list, with emideltide the exception among the peptides reviewed. The vote is nonbinding.
Caveat: Secondary source. Vote tallies were not available in the sources read. Automated access was blocked in the latest check; the summary comes from the dossier earlier read.
Verified Oct 31, 2026
- Intravenous safety pilot in two adults (Lee and Burgess, Altern Ther Health Med)
Status: Published Sept 2025. Two adults received up to 20 mg by infusion. No change in the tested blood markers and no side effects reported. Authors call for further studies.
Caveat: Two participants, no placebo. Both had received intravenous BPC-157 before. The abstract does not say where the BPC-157 came from. Full text not read.
Verified Oct 31, 2026
Records are added when we verify them against the primary source. A record here is not an endorsement of what it says. Missing items are listed on each dossier under “Still not covered.”